CENTRAL NERVOUS SYSTEM DYSFUNCTION AND THE ASSOCIATION WITH HSP70 ACTIVATION IN EXPERIMENTAL TOXIC HEPATITIS
DOI:
https://doi.org/10.5281/zenodo.18712185Keywords:
drug-induced liver injury; acetaminophen; HSP70; central nervous system; neurotoxicity; cellular stress response; experimental hepatitis.Abstract
Currently, drug-induced liver injury (DILI) remains one of the major challenges of modern medicine due to the widespread use of medications, the increasing prevalence of combination therapies, and the growing practice of self-medication without medical supervision. DILI may range from mild subclinical elevations of liver enzymes to severe acute liver failure requiring transplantation or resulting in high short-term mortality [2].
References
Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in drug-induced liver injury // Clinical Gastroenterology and Hepatology. — 2023. — Vol. 21, No. 5. — P. 1234–1246. — DOI: 10.1016/j.cgh.2022.08.028
Kaplowitz N. Drug-induced liver injury: update on mechanisms and risk factors // Hepatology. — 2021. — Vol. 73, No. 6. — P. 2486–2496. — DOI: 10.1002/hep.31514
Lee W.M. Acute liver failure including drug-induced liver injury // Clinical Liver Disease. — 2022. — Vol. 19, No. 3. — P. 67–73. — DOI: 10.1002/cld.1225
Polson J., Lee W.M. AASLD position paper: the management of acute liver failure and drug-induced liver injury // Hepatology Communications. — 2023. — Vol. 7, No. 4. — P. e1087–e1102. — DOI: 10.1002/hep4.2156
Uetrecht J., Naisbitt D.J. Idiosyncratic drug-induced liver injury: current understanding and future directions // Nature Reviews Gastroenterology & Hepatology. — 2020. — Vol. 17, No. 7. — P. 431–442. — DOI: 10.1038/s41575-020-0297-4
